Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines
Advanced Healthcare Materials · 2025-01 · 14 (1)
DOI: 10.1002/adhm.202401851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 24.10.2024. Verfasst von Yulu Teng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing, 100191…. Hauptthemen laut MEDLINE: Endoplasmic Reticulum Stress, Immunogenic Cell Death, Cancer Vaccines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Dying tumor cells regulated by immunogenic cell death (ICD) inducers are promising candidates for cancer vaccine development because of their comprehensive antigen spectrum. However, their limited immunogenicity and potential tumorigenicity hinder clinical translation. To address these challenges, a nano‐orchestrator is developed that targets the endoplasmic reticulum (ER) stress, a critical pre‐ICD event, to optimize the “precise dose” of ER stress. Using a clinical‐range irradiation fluence (50‒200 J cm −2 ) with an 808 nm laser, the release of damage associated molecular patterns (DAMPs) and antigens are precisely regulated. A fluence of 150 J cm −2 (2 W cm −2 for 75 s) increases dendritic cell maturation and antitumor T cell proliferation, providing valuable clinical insights. The ER stress nano‐orchestrator enhances both adjuvanticity and antigenicity via the protein kinase R‐like endoplasmic reticulum kinase (PERK)‐C/EBP homologous protein (CHOP) pathway to regulate ICD‐induced DAMPs and promote tumor cell apoptosis. These optimized ER stress phototherapeutic dying tumor cells can serve as prophylactic vaccines, achieving a remarkable 100% success rate against tumor rechallenge in vivo. Additionally, the nano‐orchestrator shows the potential to develop in situ therapeutic tumor vaccines when combined with anti‐PD‐L1 treatment, providing important insights into enhancing the efficacy of immune checkpoint regulators by modulating endogenous immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Peking University, Beijing, 100191, China.
ORCID-Profile: Xianrong Qi
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Teng, Y., Yang, Z., Peng, Y., Yang, Y., Chen, S., Li, J., Gao, D., Sun, W., Wu, Z., Zhou, Y., Li, X., & Qi, X. (2025). Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines. Advanced Healthcare Materials, 14(1). https://doi.org/10.1002/adhm.202401851
Vancouver
Teng Y, Yang Z, Peng Y, Yang Y, Chen S, Li J, et al. Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines. Advanced Healthcare Materials. 2025;14(1). doi:10.1002/adhm.202401851
BibTeX
@article{Teng2025,
author = {Teng, Yulu and Yang, Zhenzhen and Peng, Yiwei and Yang, Yiliang and Chen, Siyu and Li, Jiajia and Gao, Datong and Sun, Wen and Wu, Zinan and Zhou, Yanxia and Li, Xinru and Qi, Xianrong},
title = {Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {1},
doi = {10.1002/adhm.202401851}
}
EUVIMED